Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shree Ganesh Remedies Limited reported a flat Q1FY26 with revenue of ₹24.67 crore, down 0.45% YoY but up 0.97% QoQ. Specialty Chemicals contributed ₹14.30 crore while Pharma Intermediates brought in ₹9.79 crore, with exports at ₹11.98 crore and domestic sales at ₹12.11 crore. Profitability took a hit — EBITDA fell 10.19% YoY to ₹7.30 crore, margins contracted by 321 bps to 29.6%, and PAT dropped 26.09% YoY to ₹3.44 crore (EPS ₹2.68). Management attributed the slowdown to contract repricing in the CRAMS business, European market headwinds, and rising domestic competition, calling the new margin level 'more normalised and sustainable.' The company is investing in a new pilot facility this quarter, accelerating Block 7 construction, and continuing Dahej site expansion to support a future scale-up.
Short-term numbers are weak with declining profits and margins, but management is framing this as a normalisation phase backed by capex and a strong project pipeline. Shareholders may see near-term pressure on the stock, though the long-term growth story in CRAMS remains intact if new projects convert to revenue.